Use of dexamethasone in patients with chronic subdural hematoma: a systematic review




Dexamethasone, Hematoma, Subdural, Chronic, dexametasona , cronico


Introduction: Chronic subdural hematoma (CSCH) is an old collection of blood and blood degradation products in the subdural space that usually occurs in old age, predominantly affecting males. Surgical treatment is the treatment of choice in symptomatic patients, with conventional craniotomy being the most used, although it brings with it multiple complications. For this reason, in recent years the search for alternative therapies has increased, highlighting the interest in the use of glucocorticoids, especially dexamethasone (DXM), as a perioperative adjuvant or as monotherapy in HSC as it is considered an anti-inflammatory with anti-angiogenic effects and capable of inhibiting the formation of new blood vessels. The main objective of this work is to describe the efficiency, efficacy, and safety of the use of dexamethasone in patients older than 18 years with chronic subdural hematoma in comparison with surgical drainage or placebo group. Methods: The present systematic review was conducted according to PRISMA 2020 guidelines. Advanced searches were conducted between June and July 2023, in English and Spanish language, in the NEJM, PubMed and Embase databases through Cochrane Library using the descriptors and Boolean operators as follows: "Dexamethasone" AND "Hematoma, Subdural, Chronic", and custom year range 2018 - 2023. Results: 44 articles were found in the different databases, of which 12 were duplicates. Only 32 articles were reviewed for title and abstract reading. After applying the inclusion and exclusion criteria, only 10 articles were selected for a subsequent full-text review; five articles were finally included in the review. Discussion and conclusion: Apparently the use of DXM in patients with CSDH has a positive impact only on the risk of recurrence, however, no conclusive results were found. Likewise, the use of DXM in patients with CSDH is associated with an increased risk of complications and mortality, and no significant difference was demonstrated in functional outcomes and days of hospitalization compared to those who received primary surgery or placebo.


YR Y, V P, H N, J B. Chronic subdural hematoma. Asian J Neurosurg [Internet]. 2016 [cited 2023 Jul 4];11(4):613–9. Available from:

Dammers R, Holl DC, Kapiteijn B, Kompanje EJO. The first historical description of chronic subdural hematoma: A tale of inaccurate interpretation, inaccurate quoting and inaccurate requoting. J Hist Neurosci [Internet]. 2023 [cited 2023 Jul 4];32(1):1–18. Available from: DOI:

Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol [Internet]. 2014 Jan 1 [cited 2023 Jul 4];10(10):570–8. Available from: DOI:

Ramachandran R, Hegde T. Chronic subdural hematomas—causes of morbidity and mortality. Surg Neurol. 2007 Apr 1;67(4):367–72. DOI:

Gerardo Gascón Cerda, Natalia José Salazar Pérez Dr. Bayron Alexander Sandoval Bonilla, Edna Sikahall Meneses, Laura del Pilar Torres Arreola. Guía de Práctica Clínica. Diagnóstico y Tratamiento del Hematoma Subdural Crónico Tarumático en Pacientes mayores de 18 años de edad [Internet]. Ciudad de México; 2009 [cited 2023 Jul 9]. Report No.: 1. Available from:

Viaroli E, Iaccarino C, Maduri R, Daniel RT, Servadei F. Complications After Surgery for Chronic Subdural Hematomas. Complications in Neurosurgery. 2019 Jan 1;274–9. DOI:

Fountas K, Kotlia P, Panagiotopoulos V, Fotakopoulos G. The outcome after surgical vs nonsurgical treatment of chronic subdural hematoma with dexamethasone. Interdisciplinary Neurosurgery. 2019 Jun 1;16:70–4. DOI:

Yao Z, Hu X, Ma L, You C. Dexamethasone for chronic subdural haematoma: a systematic review and meta-analysis. Acta Neurochir (Wien) [Internet]. 2017 Nov 1 [cited 2023 Jul 10];159(11):2037–44. Available from: DOI:

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ [Internet]. 2021 Mar 29 [cited 2023 Jul 13];372. Available from: DOI:

Cascaes da Silva F, Beatriz Angélica Valdivia Arancibia T, da Rosa Iop R, Jose Barbosa Gutierres Filho P, da Silva R. Escalas y listas de evaluación de la calidad de estudios científicos. Revista Cubana de Información en Ciencias de la Salud [Internet]. 2013 [cited 2023 Jul 30];24(3):295–312. Available from:

Merino-Trujillo A. Como escribir documentos científicos. Artículo de revisión*. [cited 2023 Jul 21];19(3):90–4. Available from:

Diener HC. Dex-CSDH trial: dexamethasone for chronic subdural hematoma. Arzneimitteltherapie [Internet]. [cited 2023 Jul 21];(3). Available from:

Dexamethasone Therapy versus Surgery for Chronic Subdural Haematoma, a clinical randomised controlled trial (DECSA-trial) | Cochrane Library [Internet]. [cited 2023 Jul 21]. Available from:

Edlmann E, Giorgi-Coll S, Thelin EP, Hutchinson PJ, Carpenter KLH. Dexamethasone reduces vascular endothelial growth factor in comparison to placebo in post-operative chronic subdural hematoma samples: A target for future drug therapy? Front Neurol. 2022 Sep 8;13:952308. DOI:

Miah IP, Blanter A, Tank Y, van Zwet EW, Rosendaal FR, Peul WC, et al. Change in Hematoma Size after Dexamethasone Therapy in Chronic Subdural Hematoma Subtypes: A Prospective Study in Symptomatic Patients. J Neurotrauma [Internet]. 2023 Feb 1 [cited 2023 Jul 20];40(3–4):228–39. Available from: DOI:

Holl DC, Fakhry R, Dirven CMF, te Braake FAL, Begashaw OK, Moudrous W, et al. Surgery After Primary Dexamethasone Treatment for Patients with Chronic Subdural Hematoma-A Retrospective Study. World Neurosurg [Internet]. 2022 Jun 1 [cited 2023 Jul 16];162:e358–68. Available from: DOI:

Mebberson K, Colditz M, Marshman LAG, Thomas PAW, Mitchell PS, Robertson K. Prospective randomized placebo-controlled double-blind clinical study of adjuvant dexamethasone with surgery for chronic subdural haematoma with post-operative subdural drainage: Interim analysis. J Clin Neurosci [Internet]. 2020 Jan 1 [cited 2023 Jul 20];71:153–7. Available from: DOI:

Hutchinson PJ, Edlmann E, Bulters D, Zolnourian A, Holton P, Suttner N, et al. Trial of Dexamethasone for Chronic Subdural Hematoma. N Engl J Med [Internet]. 2020 Dec 31 [cited 2023 Jul 20];383(27):2616–27. Available from:

Miah IP, Holl DC, Blaauw J, Lingsma HF, den Hertog HM, Jacobs B, et al. Dexamethasone versus Surgery for Chronic Subdural Hematoma. N Engl J Med [Internet]. 2023 Jun 15 [cited 2023 Jul 20];388(24):2230–40. Available from: DOI:

Hutchinson PJ, Edlmann E, Bulters D, Zolnourian A, Holton P, Suttner N, et al. Trial of Dexamethasone for Chronic Subdural Hematoma. N Engl J Med [Internet]. 2020 Dec 31 [cited 2023 Jul 16];383(27):2616–27. Available from: DOI:

Miah IP, Herklots M, Roks G, Peul WC, Walchenbach R, Dammers R, et al. Dexamethasone Therapy in Symptomatic Chronic Subdural Hematoma (DECSA–R): A Retrospective Evaluation of Initial Corticosteroid Therapy versus Primary Surgery. [Internet]. 2019 Dec 20 [cited 2023 Jul 17];37(2):366–72. Available from: DOI:

Tariq J, Bhatti SN. Adjunctive postoperative course of dexamethasone in chronic subdural hematoma: Effect on surgical outcome. Pak J Med Sci [Internet]. 2021 Nov 1 [cited 2023 Jul 20];37(7):1877. Available from: /pmc/articles/PMC8613023 DOI:



How to Cite

Alcaraz López, D., Ayala Obeso, A., & Reyes Pérez , N. D. (2023). Use of dexamethasone in patients with chronic subdural hematoma: a systematic review. Archivos De Neurociencias, 1(Inpress).



Evidence synthesis